checkAd

     930  0 Kommentare Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients - Seite 4

    Contacts:
    Morgan Warners
    (202) 295-0124
    mwarners@gpg.com

    or

    Lizzie Hyland
    (646) 495-2706
    lhyland@gpg.com

    Lesen Sie auch

     



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients - Seite 4 DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic diseaseDenali and collaboration partner Biogen are finalizing DNL151 clinical …